Singapore, Aug. 11 -- Australian medical robotics company Vexev has raised $6 million in new funding to accelerate the path to FDA 510(k) clearance and US commercialisation of VxWave, its robotic tomographic ultrasound platform, designed to improve access to standardised vascular imaging. The raise brings Vexev's total funding to date to $19 million.

Cardiovascular disease is the world's leading cause of death, claiming nearly 20 million lives each year. Yet access to high-quality vascular imaging remains constrained by specialist availability and inconsistent image acquisition. Vexev is developing autonomous robotic imaging technology designed to help address that challenge.

VxWave combines robotics, artificial intelligence and ultraso...